Cost effectiveness of DNA diagnosis for four monogenic diseases

Journal of Medical Genetics

Volumn 34, Issue 9, 1997, Pages 741-745

  Van Der Riet, A A P M ^a   Van Hout, B A ^a   Kutten, F F H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Cost effectiveness; DNA diagnosis; Genetic counselling

Indexed keywords

ARTICLE; CHILD HEALTH; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DUCHENNE MUSCULAR DYSTROPHY; FRAGILE X SYNDROME; GENETIC COUNSELING; GENETIC RISK; HEALTH CARE COST; HUMAN; MATHEMATICAL MODEL; MONOGENIC DISORDER; MYOTONIC DYSTROPHY; PEDIGREE ANALYSIS; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGENY; RISK ASSESSMENT;

EID: 0030884679     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.34.9.741     Document Type: Article

References (21)

1. Hille E, de Kroon M. Epidemiologie van infertiliteit. Institute for MTA, Erasmus University Rotterdam, 1992.
2. Gezondheidsraad. Advies inzake planningsregeling klinische genetica. s' Gravenhage: Gezondheidsraad, 1992.
3. Emery AEH, Raeburn JA, Skinner R, Holloway S, Lewis P. Prospective study of genetic counselling. BMJ 1979;i:1253-6.
4. Sorenson JR, Scotch JP, Swazey JP, Wertz DC, Heeren TC. Reproductive plans of genetic counseling clients not eligible for prenatal diagnosis. Am J Med Genet 1987;28:345-52.
5. Frets PG. The reproductive decision after genetic counseling. Dissertation, Erasmus University Rotterdam, 1990.
6. Dankert-Roelse JE. Effects of neonatal screening for cystic fibrosis. Dissertation, University of Groningen, 1988.
7. Kaback M, Zippin D, Boyd P, Cantor R. Attitudes toward prenatal diagnosis of cystic fibrosis among parents of affected children. In: Lawson D, ed. Cystic fibrosis horizons. Chichester: John Wiley, 1994.
8. Leonard CO, Chase GA, Childs B. Genetic counseling: a consumers view. N Engl J Med 1972;287:433-9.
9. Tybkjaer HW. Behavioural changes in CF families' reproductive pattern after introduction of prenatal diagnosis. Danish CF Association, 1992.
10. Kloosterman MD. Prenatale diagnostiek, enige cijfers over de laatste jaren. Ned Tijdschr Obstet Gynaecol 1990;103:238-42.
11. Brandenburg H. Prenatal diagnosis in women of advanced maternal age. Dissertation, Erasmus University Rotterdam, 1992.
12. Beekhuis JR, Mantingh A, De Wolf BTHM, Van Lith JMM, Breed ASPM. Serumscreening van zwangeren op foetale neurale-buisdefecten en Down syndroom; eerste ervaringen in Nederland. Ned Tijdschr Geneeskd 1993;137:1303-7.
13. World Health Organization Advisory Group on Hereditary Diseases. Community approaches to the control of hereditary diseases. Unpublished WHO document HMGAVG/85.4, 1985.
14. Wildhagen MF, Verhey JBGM, et al. Cost of care of patients with cystic fibrosis in the Netherlands in 1990-1991. Thorax 1996;51:298-301.
15. Halley DJJ, van den Ouweland AMW, Van der Hout AH, Scheffer H. Overzicht van 5 jaar DNA-diagnostiek voor cysitische fyfrose. LOD Nieuwsbrief 1995;2:8-10.
16. Höweler CJ. A clinical and genetic study in myotonic dystrophy. Dissertation, Erasmus University Rotterdam, 1986.
17. Harper PS. Myotonic dystrophy. 2nd ed. London: Saunders, 1989.
18. Brunner HG, Nillesen W, Van Oost BA, et al. Presymptomatic diagnosis of myotonic dystrophy. J Med Genet 1992;29:780-4.
19. Oostra BA, Jacky PB, Brown WT, Rousseau F. Guidelines for the diagnosis of fragile X syndrome. J Med Genet 1993;30:410-13.
20. Turner AM, Robinson H, Wake S, et al. Counseling risk figures for fragile X carrier females of varying band sizes for use in predicting the likelihood of retardation in their offspring. Am J Med Genet 1994;51:458-62.
21. Van de Laar J, Ten Kate LP. Preconceptionele screening op dragerschap voor cystische fibrose. Toetsing aan de Gezondheidsraad-criteria voor genetische screening. Ned Tijdschr Geneekd 1996;9:487-91.